UPDATED May 12, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$760.00 | -0.9% | 74.9% | US$684.3b | US$850.41 | PE111.5x | E27.3% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$512.81 | 3.7% | 5.3% | US$472.0b | US$568.10 | PE30.7x | E19.6% | 1.5% | Healthcare | ||
JNJ | US$149.91 | 0.9% | -6.0% | US$360.8b | US$173.26 | PE21.1x | E6.9% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$130.06 | 2.0% | 11.0% | US$329.4b | US$141.64 | PE142.9x | E24.9% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$160.75 | -1.9% | 9.2% | US$283.9b | US$181.55 | PE47.7x | E23.2% | 3.9% | Pharmaceuticals & Biotech | ||
AZN | UK£123.70 | 2.7% | 3.1% | UK£191.8b | UK£133.20 | PE37.9x | E15.9% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$593.03 | 3.6% | 13.0% | US$226.4b | US$625.47 | PE37.5x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
DHR | US$253.38 | 2.0% | 11.5% | US$187.7b | US$272.68 | PE46.1x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
ABT | US$104.74 | -1.1% | -5.2% | US$182.2b | US$126.14 | PE32.5x | E11.3% | 2.1% | Healthcare | ||
AMGN | US$310.15 | 3.6% | 32.8% | US$166.4b | US$314.65 | PE44.2x | E17.9% | 2.9% | Pharmaceuticals & Biotech | ||
PFE | US$28.01 | -0.5% | -24.6% | US$158.7b | US$31.94 | PS2.9x | E28.9% | 6.0% | Pharmaceuticals & Biotech | ||
ISRG | US$386.70 | 1.4% | 26.7% | US$137.2b | US$420.38 | PE69x | E11.6% | n/a | Healthcare | ||
SYK | US$330.58 | 1.6% | 14.4% | US$125.9b | US$372.35 | PE37.5x | E10.5% | 1.0% | Healthcare | ||
ELV | US$539.18 | 2.3% | 17.9% | US$125.3b | US$603.31 | PE20.1x | E12.3% | 1.2% | Healthcare | ||
MDT | US$82.84 | 1.4% | -6.8% | US$110.0b | US$94.77 | PE26.2x | E9.7% | 3.3% | Healthcare | ||
VRTX | US$422.78 | 5.0% | 21.3% | US$109.1b | US$462.09 | PE27.1x | E10.3% | n/a | Pharmaceuticals & Biotech | ||
BSX | US$73.69 | 1.6% | 37.3% | US$108.3b | US$81.17 | PE61.4x | E18.1% | n/a | Healthcare | ||
REGN | US$973.80 | 1.6% | 29.7% | US$105.1b | US$1,027.63 | PE27.2x | E12.2% | n/a | Pharmaceuticals & Biotech | ||
CI | US$348.39 | 1.7% | 35.0% | US$99.0b | US$392.82 | PE27.3x | E17.8% | 1.6% | Healthcare | ||
GSK | UK£18.00 | 3.8% | 22.4% | UK£73.4b | UK£20.25 | PE16.4x | E11.9% | 3.2% | Pharmaceuticals & Biotech | ||
BMY | US$44.94 | 2.4% | -34.1% | US$91.1b | US$53.19 | PS2x | E43.8% | 5.3% | Pharmaceuticals & Biotech | ||
CSL | AU$279.18 | 1.2% | -8.9% | AU$134.9b | AU$302.14 | PE36.1x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
HCA | US$326.65 | 6.1% | 18.4% | US$85.6b | US$344.35 | PE15.6x | E6.0% | 0.8% | Healthcare | ||
GILD | US$65.96 | 1.8% | -15.6% | US$82.2b | US$82.93 | PE169.4x | E36.5% | 4.7% | Pharmaceuticals & Biotech |